Becton Dickinson (BDX) cash flow statement
TrendArc score 52 of 100 · Health 5.3 · Momentum 9.2 · Moat 5.6 · scored Nov 17, 2026 · How the score works
Free cash flow, fiscal year to September 30, 2025
$2.7 billion
down 13.1% from the year before
Becton Dickinson generated $2.7 billion of free cash flow in the fiscal year to September 2025: $3.4 billion of cash from operations less $760 million of capital spending. That was 12.2% of revenue, against 15.2% the year before.
What stands out
- Net share repurchases of $1.0 billion and dividends of $1.2 billion came to 82% of free cash flow in the fiscal year to September 2025.
- It paid cash dividends in each of the last ten fiscal years.
Each sentence is written by a fixed rule from the figures on this page.
Free cash flow and net income, the last 10 fiscal years
Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.
Where the cash wentFiscal year to September 30, 2025
- Cash from operations 3.4
- Capital spending -0.8
- Free cash flow 2.7
- Investments bought and sold, net 0.4
- Net share repurchases -1.0
- Dividends -1.2
- Debt and other -1.9
- Net change in cash -1.0
In billions of US dollars. Outflows are grey, not red: a buyback is not a loss. "Debt and other" closes the gap to the reported change in cash. Buying marketable securities moves cash into short-term investments; the balance sheet shows both.
Cash flow statement, the last 10 fiscal years
| Fiscal year to | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | 1.7 | 1.7 | 1.5 | 1.8 | 2.1 | 0.9 | 1.2 | 0.3 | 1.1 | 1.0 |
| Depreciation and amortisation | 2.5 | 2.3 | 2.3 | 2.2 | 2.2 | 2.1 | 2.3 | 2.0 | 1.1 | 1.1 |
| Stock-based pay | 0.3 | 0.2 | 0.3 | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 | 0.3 | 0.2 |
| Working capital and other items | -1.0 | -0.4 | -1.0 | -1.6 | 0.1 | 0.3 | -0.5 | 0.2 | 0.1 | 0.3 |
| Cash from operations | 3.4 | 3.8 | 3.0 | 2.6 | 4.6 | 3.5 | 3.3 | 2.9 | 2.5 | 2.6 |
| Investing activities | ||||||||||
| Capital spending | -0.8 | -0.7 | -0.9 | -1.0 | -1.2 | -0.8 | -1.0 | -0.9 | -0.7 | -0.7 |
| Businesses bought and sold, net | 0.0 | -3.9 | 0.5 | -2.1 | -0.5 | -0.2 | 0.5 | -14.6 | 0.0 | 0.2 |
| Investments bought and sold, net | 0.4 | -0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other investing | -0.5 | -0.4 | -0.4 | -0.2 | -0.2 | -0.3 | -0.3 | -0.2 | -0.1 | -0.1 |
| Cash from investing | -0.8 | -5.5 | -0.7 | -3.2 | -1.9 | -1.2 | -0.7 | -15.7 | -0.9 | -0.7 |
| Financing activities | ||||||||||
| Debt issued or repaid, net | -1.3 | 3.8 | -0.7 | -0.1 | -0.2 | -1.8 | -2.0 | 1.1 | 7.3 | -1.3 |
| Shares issued less bought back | -1.0 | -0.5 | 0.0 | -0.5 | -1.8 | 2.9 | 0.0 | 0.0 | 4.6 | 0.0 |
| Dividends paid | -1.2 | -1.1 | -1.1 | -1.1 | -1.0 | -1.0 | -1.0 | -0.9 | -0.7 | -0.6 |
| Other financing | -0.1 | -0.1 | -0.1 | 1.1 | -0.3 | -0.1 | -0.2 | -0.2 | -0.2 | 0.1 |
| Cash from financing | -3.6 | 2.1 | -2.0 | -0.6 | -3.3 | 0.0 | -3.2 | -0.1 | 11.0 | -1.8 |
| Net change in cash | -1.0 | 0.4 | 0.3 | -1.2 | -0.5 | 2.3 | -0.6 | -12.9 | 12.6 | 0.1 |
| Free cash flow | ||||||||||
| Free cash flow | 2.7 | 3.1 | 2.1 | 1.7 | 3.5 | 2.8 | 2.4 | 2.0 | 1.8 | 1.9 |
| Free cash flow margin | 12.2% | 15.2% | 10.9% | 8.8% | 18.0% | 17.2% | 13.7% | 12.3% | 15.1% | 14.9% |
Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.
Becton Dickinson against its peers
| Company | Fiscal year to | Free cash flow | Free cash flow margin |
|---|---|---|---|
| ResMedRMD | Jun 2026 | $1.65B | 29.2% |
| Idexx LaboratoriesIDXX | Dec 2025 | $1.04B | 24.2% |
| DexcomDXCM | Dec 2025 | $1.08B | 23.1% |
| Edwards LifesciencesEW | Dec 2025 | $1.33B | 22.0% |
| Boston ScientificBSX | Dec 2025 | $3.66B | 18.2% |
| StrykerSYK | Dec 2025 | $4.28B | 17.1% |
| MedtronicMDT | Apr 2026 | $5.43B | 14.9% |
| Becton DickinsonBDX | Sep 2025 | $2.67B | 12.2% |
| GE HealthCareGEHC | Dec 2025 | $1.50B | 7.3% |
| Peer median | 20.1% |
Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.
Next
Follow Becton Dickinson with a free account.
A watchlist, price alerts and saved chart layouts. No card needed.
Sign up freeNo forecast, no recommendation. This page describes Becton Dickinson from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.
The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.